Skip to main content
Erschienen in: Drug Safety 1/2006

01.01.2006 | Original Research Article

Short-Term Chloral Hydrate Administration and Cancer in Humans

verfasst von: Dr Tmirah Haselkorn, Alice S. Whittemore, Natalia Udaltsova, Gary D. Friedman

Erschienen in: Drug Safety | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Objective: Chloral hydrate, used as a hypnosedative in adults and children, has been shown to be genotoxic and carcinogenic in animal studies. We investigated the potential causal association between chloral hydrate exposure and cancer risk in humans.
Methods: Cancer incidence was previously determined via biennial screening analyses of the 215 most commonly used drugs between 1976 and 1998 for a cohort of 143 574 outpatients at Kaiser Permanente who had prescriptions filled between 1969 and 1973. Among users of chloral hydrate, statistically significant elevations in standardised morbidity ratios were observed during various years for cancer at five anatomical sites, including the lung, stomach, prostate, skin melanoma and mouth floor. In this analysis, these associations were investigated using: (i) a dose-response analysis among exposed subjects; and (ii) a two-stage design with exposed and non-exposed persons.
Results: There was evidence of an increasing risk of prostate cancer with increasing number of dispensings of chloral hydrate, which persisted after controlling for benign prostatic hypertrophy, vasectomy and obesity; however, the trend was not statistically significant. There was no evidence of a dose-response relationship between chloral hydrate and risk of any of the other four cancers. In the two-stage design, analyses comparing exposed and unexposed subjects showed no increased risk of cancer after controlling for confounding variables; however, the data were suggestive for prostate cancer, where the increased risk associated with chloral hydrate exposure after adjustment for confounding variables persisted. No dose-response relationship was seen for any of the other four cancer sites.
Conclusions: To our knowledge, this is the first study to examine the relationship between chloral hydrate exposure and cancer risk in humans. There was no persuasive evidence to support a causal relationship between chloral hydrate exposure in humans and the development of cancer. However, statistical power was low for weak associations, particularly for some of the individual cancer sites. Although animal data using much higher doses of chloral hydrate have demonstrated its genotoxicity and carcinogenicity, the effects of chloral hydrate in humans are still uncertain.
Literatur
1.
Zurück zum Zitat Graham SR, Day RO, Lee R, et al. Overdose with chloral hydrate: a pharmacological and therapeutic review. Med J Aust 1988; 149: 686–8PubMed Graham SR, Day RO, Lee R, et al. Overdose with chloral hydrate: a pharmacological and therapeutic review. Med J Aust 1988; 149: 686–8PubMed
3.
Zurück zum Zitat Steinberg AD. Should chloral hydrate be banned? Pediatrics 1993; 92: 442–6PubMed Steinberg AD. Should chloral hydrate be banned? Pediatrics 1993; 92: 442–6PubMed
4.
Zurück zum Zitat Leuschner J, Beuscher N. Studies on the mutagenic and carcinogenic potential of chloral hydrate. Arzneimittel Forschung 1998; 48: 961–8PubMed Leuschner J, Beuscher N. Studies on the mutagenic and carcinogenic potential of chloral hydrate. Arzneimittel Forschung 1998; 48: 961–8PubMed
5.
Zurück zum Zitat Ludwigs U, Divino Filho J, Magnusson A, et al. Suicidal chloral hydrate poisoning. J Toxicol Clin Toxicol 1996; 34: 97–9PubMedCrossRef Ludwigs U, Divino Filho J, Magnusson A, et al. Suicidal chloral hydrate poisoning. J Toxicol Clin Toxicol 1996; 34: 97–9PubMedCrossRef
6.
Zurück zum Zitat Harrington-Brock K, Doerr CL, Moore MM. Mutagenicity of three disinfection by-products: di- and trichloroacetic acid and chloral hydrate in L5178Y/TK +/− (−) 3.7.2C mouse lymphoma cells. Mutat Res 1998; 413: 265–76PubMedCrossRef Harrington-Brock K, Doerr CL, Moore MM. Mutagenicity of three disinfection by-products: di- and trichloroacetic acid and chloral hydrate in L5178Y/TK +/− (−) 3.7.2C mouse lymphoma cells. Mutat Res 1998; 413: 265–76PubMedCrossRef
7.
Zurück zum Zitat IARC. Chloral and chloral hydrate. IARC Monogr Eval Carcinog Risk Chem Hum 1995; 63: 245 IARC. Chloral and chloral hydrate. IARC Monogr Eval Carcinog Risk Chem Hum 1995; 63: 245
8.
Zurück zum Zitat Salmon AG, Kizer KW, Zeise L, et al. Potential carcinogenicity of chloral hydrate: a review. J Toxicol Clin Toxicol 1995; 33: 115–21PubMedCrossRef Salmon AG, Kizer KW, Zeise L, et al. Potential carcinogenicity of chloral hydrate: a review. J Toxicol Clin Toxicol 1995; 33: 115–21PubMedCrossRef
9.
Zurück zum Zitat Allen JW, Liang JC, Carrano AV, et al. Review of literature on chemical-induced aneuploidy in mammalian male germ cells. Mutat Res 1986; 167: 123–37PubMedCrossRef Allen JW, Liang JC, Carrano AV, et al. Review of literature on chemical-induced aneuploidy in mammalian male germ cells. Mutat Res 1986; 167: 123–37PubMedCrossRef
10.
Zurück zum Zitat Eichenlaub-Ritter U, Betzendahl I. Chloral hydrate induced spindle aberrations, metaphase I arrest and aneuploidy in mouse oocytes. Mutagenesis 1995; 10: 477–86PubMedCrossRef Eichenlaub-Ritter U, Betzendahl I. Chloral hydrate induced spindle aberrations, metaphase I arrest and aneuploidy in mouse oocytes. Mutagenesis 1995; 10: 477–86PubMedCrossRef
11.
Zurück zum Zitat Faust JB. Evidence on the carcinogenicity of chloral hydrate (2003 update). Sacramento (CA): Reproductive and Cancer Hazard Assessment Section, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, 2003: 1–29 Faust JB. Evidence on the carcinogenicity of chloral hydrate (2003 update). Sacramento (CA): Reproductive and Cancer Hazard Assessment Section, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, 2003: 1–29
12.
Zurück zum Zitat Steinberg AD, DeSesso JM. Have animal data been used inappropriately to estimate risks to humans from environmental trichloroethylene? Regul Toxicol Pharmacol 1993; 18: 137–53PubMedCrossRef Steinberg AD, DeSesso JM. Have animal data been used inappropriately to estimate risks to humans from environmental trichloroethylene? Regul Toxicol Pharmacol 1993; 18: 137–53PubMedCrossRef
13.
Zurück zum Zitat IARC. Trichloroethylene. IARC Monogr Eval Carcinog Risk Chem Hum 1995; 63: 75 IARC. Trichloroethylene. IARC Monogr Eval Carcinog Risk Chem Hum 1995; 63: 75
14.
Zurück zum Zitat Roe FJ, Salaman MH. Further studies on incomplete carcinogenesis: triethylene melamine (T.E.M.), 1,2-benzanthracene and beta-propiolactone, as initiators of skin tumour formation in the mouse. Br J Cancer 1955; 9: 177–203PubMedCrossRef Roe FJ, Salaman MH. Further studies on incomplete carcinogenesis: triethylene melamine (T.E.M.), 1,2-benzanthracene and beta-propiolactone, as initiators of skin tumour formation in the mouse. Br J Cancer 1955; 9: 177–203PubMedCrossRef
15.
Zurück zum Zitat Rijhsinghani KS, Abrahams C, Swerdlow MA, et al. Induction of neoplastic lesions in the livers of C57BL × C3HF1 mice by chloral hydrate. Cancer Detect Prev 1986; 9: 279–88PubMed Rijhsinghani KS, Abrahams C, Swerdlow MA, et al. Induction of neoplastic lesions in the livers of C57BL × C3HF1 mice by chloral hydrate. Cancer Detect Prev 1986; 9: 279–88PubMed
16.
Zurück zum Zitat Daniel FB, DeAngelo AB, Stober JA, et al. Hepatocarcinogenicity of chloral hydrate, 2-chloroacetaldehyde, and dichloroacetic acid in the male B6C3F1 mouse. Fundam Appl Toxicol 1992; 19: 159–68PubMedCrossRef Daniel FB, DeAngelo AB, Stober JA, et al. Hepatocarcinogenicity of chloral hydrate, 2-chloroacetaldehyde, and dichloroacetic acid in the male B6C3F1 mouse. Fundam Appl Toxicol 1992; 19: 159–68PubMedCrossRef
17.
Zurück zum Zitat Beland FA. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0): administered by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser 1999 Aug; (59): 1–66, A1-E7PubMed Beland FA. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0): administered by gavage to F344/N rats and B6C3F1 mice. Toxic Rep Ser 1999 Aug; (59): 1–66, A1-E7PubMed
18.
Zurück zum Zitat George MH, Moore T, Kilburn S, et al. Carcinogenicity of chloral hydrate administered in drinking water to the male F344/N rat and male B6C3F1 mouse. Toxicol Pathol 2000; 28: 610–8PubMedCrossRef George MH, Moore T, Kilburn S, et al. Carcinogenicity of chloral hydrate administered in drinking water to the male F344/N rat and male B6C3F1 mouse. Toxicol Pathol 2000; 28: 610–8PubMedCrossRef
19.
Zurück zum Zitat NTP. Toxicology and carcinogenesis studies of chloral hydrate (CAS No. 302-17-0) in male (ad libitum and dietary controlled) B6C3F1 mice (Gavage study), Research Triangle Park (NC): National Institutes of Health, National Toxicology Program; 2002b NTP Technical Report Series No. 503: USDHHS, PHS NTP. Toxicology and carcinogenesis studies of chloral hydrate (CAS No. 302-17-0) in male (ad libitum and dietary controlled) B6C3F1 mice (Gavage study), Research Triangle Park (NC): National Institutes of Health, National Toxicology Program; 2002b NTP Technical Report Series No. 503: USDHHS, PHS
20.
Zurück zum Zitat Seng JE, Agrawal N, Horsley ET, et al. Toxicokinetics of chloral hydrate in ad libitum-fed, dietary-controlled, and calorically restricted male B6C3F1 mice following short-term exposure. Toxicol Appl Pharmacol 2003; 193: 281–92PubMedCrossRef Seng JE, Agrawal N, Horsley ET, et al. Toxicokinetics of chloral hydrate in ad libitum-fed, dietary-controlled, and calorically restricted male B6C3F1 mice following short-term exposure. Toxicol Appl Pharmacol 2003; 193: 281–92PubMedCrossRef
21.
Zurück zum Zitat Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980; 65: 723–33PubMed Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980; 65: 723–33PubMed
22.
Zurück zum Zitat Friedman GD, Ury HK. Screening for possible drug carcinogenicity: second report of findings. J Natl Cancer Inst 1983; 71: 1165–75PubMed Friedman GD, Ury HK. Screening for possible drug carcinogenicity: second report of findings. J Natl Cancer Inst 1983; 71: 1165–75PubMed
23.
Zurück zum Zitat Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989; 49: 5736–47PubMed Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989; 49: 5736–47PubMed
24.
Zurück zum Zitat White JE. A two stage design for the study of the relationship between a rare exposure and a rare disease. Am J Epidemiol 1982; 115: 119–28PubMed White JE. A two stage design for the study of the relationship between a rare exposure and a rare disease. Am J Epidemiol 1982; 115: 119–28PubMed
25.
Zurück zum Zitat Weinberg CR, Wacholder S. The design and analysis of case-control studies with biased sampling. Biometrics 1990; 46: 963–75PubMedCrossRef Weinberg CR, Wacholder S. The design and analysis of case-control studies with biased sampling. Biometrics 1990; 46: 963–75PubMedCrossRef
26.
Zurück zum Zitat Chloral hydrate: US Environmental Protection Agency Integrated Risk Information Systems (IRIS) [online]. Available from URL: http://www.epa.gov/iris/subst/0304.htm [Accessed 2001 Jan 2] Chloral hydrate: US Environmental Protection Agency Integrated Risk Information Systems (IRIS) [online]. Available from URL: http://​www.​epa.​gov/​iris/​subst/​0304.​htm [Accessed 2001 Jan 2]
27.
Zurück zum Zitat Leakey JE, Seng JE, Latendresse JR, et al. Dietary controlled carcinogenicity study of chloral hydrate in male B6C3F1 mice. Toxicol Appl Pharmacol 2003; 193: 266–80PubMedCrossRef Leakey JE, Seng JE, Latendresse JR, et al. Dietary controlled carcinogenicity study of chloral hydrate in male B6C3F1 mice. Toxicol Appl Pharmacol 2003; 193: 266–80PubMedCrossRef
28.
Zurück zum Zitat Goodman LS, Gilman A. The pharmacological basis of therapeutics. New York (NY): The Macmillan Co, 1985 Goodman LS, Gilman A. The pharmacological basis of therapeutics. New York (NY): The Macmillan Co, 1985
29.
Zurück zum Zitat Bull RJ. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ Health Perspect 2000; 108: 241–59PubMedCrossRef Bull RJ. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ Health Perspect 2000; 108: 241–59PubMedCrossRef
30.
Zurück zum Zitat Laughter AR, Dunn CS, Swanson CL, et al. Role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology 2004; 203: 83–98PubMedCrossRef Laughter AR, Dunn CS, Swanson CL, et al. Role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology 2004; 203: 83–98PubMedCrossRef
31.
Zurück zum Zitat Walgren JL, Jollow DJ, McMillan JM. Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates. Toxicology 2004; 197: 189–97PubMedCrossRef Walgren JL, Jollow DJ, McMillan JM. Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates. Toxicology 2004; 197: 189–97PubMedCrossRef
32.
Zurück zum Zitat Austin EW, Okita JR, Okita RT, et al. Modification of lipoperoxidative effects of dichloroacetate and trichloroacetate is associated with peroxisome proliferation. Toxicology 1995; 97: 59–69PubMedCrossRef Austin EW, Okita JR, Okita RT, et al. Modification of lipoperoxidative effects of dichloroacetate and trichloroacetate is associated with peroxisome proliferation. Toxicology 1995; 97: 59–69PubMedCrossRef
33.
Zurück zum Zitat Stephen RL, Gustafsson MC, Jarvis M, et al. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 2004; 64: 3162–70PubMedCrossRef Stephen RL, Gustafsson MC, Jarvis M, et al. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 2004; 64: 3162–70PubMedCrossRef
Metadaten
Titel
Short-Term Chloral Hydrate Administration and Cancer in Humans
verfasst von
Dr Tmirah Haselkorn
Alice S. Whittemore
Natalia Udaltsova
Gary D. Friedman
Publikationsdatum
01.01.2006
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 1/2006
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200629010-00005

Weitere Artikel der Ausgabe 1/2006

Drug Safety 1/2006 Zur Ausgabe